Aigen Investment Management LP Has $223,000 Stock Holdings in Becton, Dickinson and Company (NYSE:BDX)

Aigen Investment Management LP decreased its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 58.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 985 shares of the medical instruments supplier’s stock after selling 1,377 shares during the quarter. Aigen Investment Management LP’s holdings in Becton, Dickinson and Company were worth $223,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Bank of Jackson Hole Trust acquired a new position in Becton, Dickinson and Company during the fourth quarter worth $25,000. Sierra Ocean LLC bought a new stake in shares of Becton, Dickinson and Company during the 4th quarter worth about $29,000. Ashton Thomas Securities LLC acquired a new position in shares of Becton, Dickinson and Company during the 3rd quarter valued at about $33,000. Tompkins Financial Corp raised its stake in shares of Becton, Dickinson and Company by 44.2% in the 3rd quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock valued at $36,000 after acquiring an additional 46 shares in the last quarter. Finally, Kennebec Savings Bank acquired a new stake in Becton, Dickinson and Company in the 3rd quarter worth approximately $46,000. Institutional investors own 86.97% of the company’s stock.

Insider Activity

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 2,838 shares of the firm’s stock in a transaction dated Thursday, December 19th. The shares were sold at an average price of $223.33, for a total transaction of $633,810.54. Following the completion of the transaction, the executive vice president now owns 6,141 shares in the company, valued at $1,371,469.53. This trade represents a 31.61 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Shana Carol Neal sold 788 shares of Becton, Dickinson and Company stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $235.00, for a total value of $185,180.00. Following the sale, the executive vice president now directly owns 16,201 shares in the company, valued at $3,807,235. The trade was a 4.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 5,423 shares of company stock worth $1,239,780. Company insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Price Performance

Shares of Becton, Dickinson and Company stock opened at $229.51 on Monday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.13 and a quick ratio of 0.63. The company has a market cap of $65.90 billion, a PE ratio of 38.12, a price-to-earnings-growth ratio of 1.63 and a beta of 0.35. The firm has a fifty day moving average price of $232.98 and a two-hundred day moving average price of $232.71. Becton, Dickinson and Company has a fifty-two week low of $218.75 and a fifty-two week high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share for the quarter, beating the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. Analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company declared that its Board of Directors has initiated a share buyback plan on Tuesday, January 28th that authorizes the company to buyback 10,000,000 shares. This buyback authorization authorizes the medical instruments supplier to repurchase shares of its stock through open market purchases. Shares buyback plans are typically an indication that the company’s board believes its shares are undervalued.

Becton, Dickinson and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Stockholders of record on Monday, March 10th will be issued a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a dividend yield of 1.81%. The ex-dividend date is Monday, March 10th. Becton, Dickinson and Company’s payout ratio is presently 69.10%.

Analyst Ratings Changes

BDX has been the topic of a number of recent analyst reports. Piper Sandler lifted their price target on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a research report on Tuesday, January 28th. Barclays lifted their target price on shares of Becton, Dickinson and Company from $278.00 to $279.00 and gave the stock an “overweight” rating in a report on Friday, February 14th. Finally, StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Wednesday, March 5th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $278.29.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.